NDAORALTABLET
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
TEVETEN (eprosartan mesylate) by AbbVie is mechanism of action eprosartan: angiotensin ii (formed from angiotensin i in a reaction catalyzed by angiotensin-converting enzyme [kininase ii]), a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Approved for hypertension. First approved in 1997.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVETEN (eprosartan mesylate) is an oral angiotensin II receptor blocker (ARB) approved in 1997 for the treatment of hypertension. It selectively blocks AT1 receptors to reduce vasoconstriction and aldosterone secretion, lowering blood pressure through a mechanism independent of ACE inhibition. The drug is available as a monotherapy tablet and in combination with hydrochlorothiazide (TEVETEN HCT).
LOE Approaching
With loss of exclusivity approaching and competitive pressure at 30%, the TEVETEN team is likely focused on generic transition planning and cost-containment strategies rather than expansion initiatives.
Mechanism of Action
Mechanism of Action Eprosartan: Angiotensin II (formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]), a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Angiotensin II also stimulates aldosterone synthesis and…
Worked on TEVETEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.